JP2009502914A5 - - Google Patents

Download PDF

Info

Publication number
JP2009502914A5
JP2009502914A5 JP2008523847A JP2008523847A JP2009502914A5 JP 2009502914 A5 JP2009502914 A5 JP 2009502914A5 JP 2008523847 A JP2008523847 A JP 2008523847A JP 2008523847 A JP2008523847 A JP 2008523847A JP 2009502914 A5 JP2009502914 A5 JP 2009502914A5
Authority
JP
Japan
Prior art keywords
disorders
withdrawal
substance
withdrawal symptoms
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008523847A
Other languages
English (en)
Japanese (ja)
Other versions
JP5094720B2 (ja
JP2009502914A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/026439 external-priority patent/WO2007018496A1/en
Publication of JP2009502914A publication Critical patent/JP2009502914A/ja
Publication of JP2009502914A5 publication Critical patent/JP2009502914A5/ja
Application granted granted Critical
Publication of JP5094720B2 publication Critical patent/JP5094720B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008523847A 2005-07-26 2005-07-26 サブスタンス関連障害を処置する方法 Expired - Fee Related JP5094720B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/026439 WO2007018496A1 (en) 2005-07-26 2005-07-26 Methods for treating substance-related disorders

Publications (3)

Publication Number Publication Date
JP2009502914A JP2009502914A (ja) 2009-01-29
JP2009502914A5 true JP2009502914A5 (cg-RX-API-DMAC10.html) 2012-03-29
JP5094720B2 JP5094720B2 (ja) 2012-12-12

Family

ID=35064669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008523847A Expired - Fee Related JP5094720B2 (ja) 2005-07-26 2005-07-26 サブスタンス関連障害を処置する方法

Country Status (13)

Country Link
EP (1) EP1928451B1 (cg-RX-API-DMAC10.html)
JP (1) JP5094720B2 (cg-RX-API-DMAC10.html)
KR (1) KR101199499B1 (cg-RX-API-DMAC10.html)
CN (1) CN101272776B (cg-RX-API-DMAC10.html)
AT (1) ATE538784T1 (cg-RX-API-DMAC10.html)
AU (1) AU2005335241B9 (cg-RX-API-DMAC10.html)
BR (1) BRPI0520451A2 (cg-RX-API-DMAC10.html)
CA (1) CA2616721C (cg-RX-API-DMAC10.html)
EA (1) EA019935B1 (cg-RX-API-DMAC10.html)
ES (1) ES2385087T3 (cg-RX-API-DMAC10.html)
IL (1) IL189003A0 (cg-RX-API-DMAC10.html)
NO (1) NO20080877L (cg-RX-API-DMAC10.html)
WO (1) WO2007018496A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1890684T3 (pl) 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
AU2010270971B2 (en) 2009-06-22 2015-08-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
ES2447295T3 (es) 2009-11-06 2014-03-11 Sk Biopharmaceuticals Co., Ltd. Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
RU2019114940A (ru) 2013-03-13 2019-06-28 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии
DK3021838T3 (da) 2013-07-18 2020-08-24 Jazz Pharmaceuticals Ireland Ltd Behandling af fedme
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
KR20200016889A (ko) 2017-06-02 2020-02-17 재즈 파마슈티칼즈 아일랜드 리미티드 과다 졸림증을 치료하기 위한 방법 및 조성물
US12502371B2 (en) 2019-06-27 2025-12-23 Numan Labo Llc Drug for treating and preventing dementia
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
DE60223506T2 (de) * 2001-02-27 2008-09-18 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung oder behandlung bipolarer erkrankungen
RS50676B (sr) * 2001-02-27 2010-06-30 Ortho-Mcneil Pharmaceutical Inc. Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
DK1401424T3 (da) * 2001-02-27 2007-02-26 Ortho Mcneil Pharm Inc Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af psykotiske forstyrrelser
DE60220043T2 (de) * 2001-02-27 2008-01-10 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection

Similar Documents

Publication Publication Date Title
Dome et al. Smoking, nicotine and neuropsychiatric disorders
Clark et al. The role of dynorphin and the kappa opioid receptor in the symptomatology of schizophrenia: a review of the evidence
Kumru et al. Rapid eye movement sleep behavior disorder in parkinsonism with parkin mutations
Scammell et al. Orexin receptors: pharmacology and therapeutic opportunities
Murray et al. Insomnia caused by serotonin depletion is due to hypothermia
Hassan et al. Novel psychoactive substances—recent progress on neuropharmacological mechanisms of action for selected drugs
JP2019031502A5 (cg-RX-API-DMAC10.html)
JP2008534627A5 (cg-RX-API-DMAC10.html)
JP6421185B2 (ja) ベンゾイミダゾール−プロリン誘導体の使用
AU2021206771B2 (en) Cognitive disorder prevention and therapy
JP2017535612A5 (cg-RX-API-DMAC10.html)
JP2003504303A5 (cg-RX-API-DMAC10.html)
Niaura et al. Varenicline
EA200601611A1 (ru) Терапия с применением производных 1-аминоциклогексана для лечения поведенческих нарушений, ассоциированных с болезнью альцгеймера
Manconi et al. Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome
US20040266659A1 (en) Substances that enhance recall and lucidity during dreaming
Breuer et al. “Herbal seizures”–atypical symptoms after ibogaine intoxication: a case report
Bin et al. Preliminary evaluation of the efficacy and safety of brimonidine for general anesthesia
WO2009064836A3 (en) Kynurenine-aminotransferase inhibitors
Bala et al. Psychiatric and anesthetic implications of substance abuse: Present scenario
JP2008526706A5 (cg-RX-API-DMAC10.html)
CN101272776A (zh) 治疗物质滥用相关疾病的方法
Kjellgren et al. The quest for well-being and pleasure: experiences of the novel synthetic opioids AH-7921 and MT-45, as reported by anonymous users online.
JP2008507550A5 (cg-RX-API-DMAC10.html)
JP2010505919A5 (cg-RX-API-DMAC10.html)